Insight, China's Pharmaceutical Industry

Guangdong’s OptoMedic Secures Over $27.8 Million in Pre-IPO Financing for Endoscopy Innovations

Fineline Cube Jul 12, 2023

OptoMedic Technologies, Inc., a leading endoscopy specialist based in Guangdong, has reportedly raised upwards of...

Jiangsu Hengrui Pharmaceuticals’ Irinotecan and Bupivacaine Liposome Injections Get Clinical Trial Green Light in China

Fineline Cube Jul 12, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a China-based pharmaceutical company, has announced receiving separate...

Company Drug

Shanghai Junshi Biosciences’ Tuoyi Files for 9th Indication in China for RCC Treatment

Fineline Cube Jul 12, 2023

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the National Medical...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives Clinical Trial Approvals for Irinotecan and Bupivacaine Liposome Injections

Fineline Cube Jul 12, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a China-based pharmaceutical company, has announced receiving separate...

Company Drug

Shanghai Junshi Biosciences’ Tuoyi Files for 9th Indication in China for RCC Treatment

Fineline Cube Jul 12, 2023

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the National Medical...

Company Deals

Next Generation Gene Therapeutics Secures $40 Million in Series B Financing for Gene Therapy Development

Fineline Cube Jul 12, 2023

Next Generation Gene Therapeutics Inc., a leading gene therapy developer based in Suzhou, China, has...

Company Deals

Ji Xing Pharmaceuticals and TSH Biopharm Announce Collaboration for Dry Eye Treatment in Taiwan

Fineline Cube Jul 12, 2023

Shanghai-based Ji Xing Pharmaceuticals, a company backed by RTW Investments, has announced a strategic collaboration...

Company Drug

Hrain Biotechnology’s Anti-CD70 T Cell Therapy HR010 Gets Tacit Approval for Renal Cancer Trial

Fineline Cube Jul 12, 2023

Shanghai-based Hrain Biotechnology Co., Ltd. has announced receiving tacit clinical trial approval from the Center...

Company Drug

Huadong Medicine’s Elahere Receives Approval for FRα Positive Cancer Treatment in China

Fineline Cube Jul 12, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving approval to introduce Elahere (mirvetuximab...

Company Deals

WuXi Biologics Proposes Spin-Off and Listing of WuXi XDC on Hong Kong Stock Exchange

Fineline Cube Jul 11, 2023

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced the...

Company Drug

Jiangxi Jemincare Group Launches Omalizumab Biosimilar CMAB007 in China for Asthma and Dermatology

Fineline Cube Jul 11, 2023

Jiangxi Jemincare Group has overseen the official launch and first prescription of its omalizumab biosimilar,...

Company Deals

Zhejiang Doer Biologics Partners with BioNTech for Global Development of Innovative Biological Drugs

Fineline Cube Jul 11, 2023

Zhejiang Doer Biologics Co., Ltd, a China-based clinical-stage biopharmaceutical company, has announced a significant licensing...

Company Drug

C4 Therapeutics’ CFT8919 Earns FDA Approval for Clinical Trials Targeting EGFR L858R Mutations

Fineline Cube Jul 11, 2023

US-based C4 Therapeutics Inc., (NASDAQ: CCCC) has announced receiving clinical trial approval from the US...

Policy / Regulatory

NHSA’s 2022 Report: BMI Fund Income Rises 7.6%, Outgoing Expenditure Increases 2.3%

Fineline Cube Jul 11, 2023

The National Healthcare Security Administration (NHSA) has released its annual statistical report for 2022, detailing...

Company Drug

Zai Lab’s Vyvgart Receives NMPA Review for Subcutaneous Injection Form in gMG Treatment

Fineline Cube Jul 11, 2023

China-based Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced that the National Medical Products...

Company Medical Device

Sino Medical Sciences Receives Approval for Next-Generation Drug-Eluting Stent in Indonesia

Fineline Cube Jul 11, 2023

China-based Sino Medical Sciences Technology Inc., (SHA: 688108) has announced receiving market approval for its...

Policy / Regulatory

Shanghai’s SMPA Initiates Volume-Based Procurement for National VBP Drugs in Alliance Region

Fineline Cube Jul 11, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has released a notification indicating the commencement of follow-up...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for HRS-9815 Radiodiagnostic Drug Clinical Study

Fineline Cube Jul 11, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a China-based pharmaceutical company, has announced receiving approval...

Company Deals

Everest Medicines and Sinopharm Group Ink MoU to Enhance Distribution and Collaboration

Fineline Cube Jul 11, 2023

China-based Everest Medicines (HKG: 1952) has announced the signing of a memorandum of understanding (MoU)...

Company Deals

BeiGene Secures Exclusive Licensing Deal with Duality Biotherapeutics for Novel Drug Development

Fineline Cube Jul 11, 2023

China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced an exclusive option and licensing...

Insight, China's Pharmaceutical Industry

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

SenseTime Raises $73.3 Million in Series A Financing for AI Healthcare Platform – Medical Agentic OS and World Model Capabilities Attract Raffles Healthcare, Lion Partners

Mabwell Bioscience Raises $185 Million in Hong Kong IPO After Two Previous Failed Attempts – Oncology and Age-Related Disease Developer Secures HK$1.45 Billion Valuation

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Novo Nordisk’s Oral Etavopivat Meets Primary Endpoints in Phase III HIBISCUS Trial for Sickle Cell Disease; Regulatory Filing Planned for H2 2026

Akeso’s Cadonilimab Shows Promise in First-Line Pancreatic Cancer at AACR 2026; Dual PD-1/CTLA-4 Bispecific Gains Guideline Endorsements Across Seven Cancers

Guangdong’s OptoMedic Secures Over $27.8 Million in Pre-IPO Financing for Endoscopy Innovations

Jiangsu Hengrui Pharmaceuticals’ Irinotecan and Bupivacaine Liposome Injections Get Clinical Trial Green Light in China

Shanghai Junshi Biosciences’ Tuoyi Files for 9th Indication in China for RCC Treatment

Jiangsu Hengrui Pharmaceuticals Receives Clinical Trial Approvals for Irinotecan and Bupivacaine Liposome Injections

Shanghai Junshi Biosciences’ Tuoyi Files for 9th Indication in China for RCC Treatment

Next Generation Gene Therapeutics Secures $40 Million in Series B Financing for Gene Therapy Development

Ji Xing Pharmaceuticals and TSH Biopharm Announce Collaboration for Dry Eye Treatment in Taiwan

Hrain Biotechnology’s Anti-CD70 T Cell Therapy HR010 Gets Tacit Approval for Renal Cancer Trial

Huadong Medicine’s Elahere Receives Approval for FRα Positive Cancer Treatment in China

WuXi Biologics Proposes Spin-Off and Listing of WuXi XDC on Hong Kong Stock Exchange

Jiangxi Jemincare Group Launches Omalizumab Biosimilar CMAB007 in China for Asthma and Dermatology

Zhejiang Doer Biologics Partners with BioNTech for Global Development of Innovative Biological Drugs

C4 Therapeutics’ CFT8919 Earns FDA Approval for Clinical Trials Targeting EGFR L858R Mutations

NHSA’s 2022 Report: BMI Fund Income Rises 7.6%, Outgoing Expenditure Increases 2.3%

Zai Lab’s Vyvgart Receives NMPA Review for Subcutaneous Injection Form in gMG Treatment

Sino Medical Sciences Receives Approval for Next-Generation Drug-Eluting Stent in Indonesia

Shanghai’s SMPA Initiates Volume-Based Procurement for National VBP Drugs in Alliance Region

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for HRS-9815 Radiodiagnostic Drug Clinical Study

Everest Medicines and Sinopharm Group Ink MoU to Enhance Distribution and Collaboration

BeiGene Secures Exclusive Licensing Deal with Duality Biotherapeutics for Novel Drug Development

You Missed

Novo Nordisk’s Oral Etavopivat Meets Primary Endpoints in Phase III HIBISCUS Trial for Sickle Cell Disease; Regulatory Filing Planned for H2 2026

Akeso’s Cadonilimab Shows Promise in First-Line Pancreatic Cancer at AACR 2026; Dual PD-1/CTLA-4 Bispecific Gains Guideline Endorsements Across Seven Cancers

LEO Pharma Secures NMPA Approval for Enstilar Foam in China – First and Only Calcipotriol/Betamethasone Foam Formulation for Plaque Psoriasis Demonstrates Superior Efficacy vs. Ointment

Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication